A373110 Stock Overview

Engages in the development and production of drugs for cell therapy. More details

A373110 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Earnings have declined by 6.6% per year over past 5 years

Does not have meaningful revenue (₩2B)

Volatile share price over the past 3 months compared to the KR market

Does not have a meaningful market cap (₩44B)

My Notes

Capture your thoughts, links and company narrative

Xcell Therapeutics Inc. Competitors

GENINUS

KOSDAQ:A389030

₩46.4b

Daesung Microbiological Labs

KOSDAQ:A036480

₩34.7b

Genesystem

KOSDAQ:A363250

₩58.9b

Seoulin BioscienceLtd

KOSDAQ:A038070

₩62.5b

Price History & Performance

Summary of share price highs, lows and changes for Xcell Therapeutics
Historical stock prices
Current Share Price	₩4,155.00
52 Week High	₩12,900.00
52 Week Low	₩3,385.00
Beta	0
1 Month Change	-13.26%
3 Month Change	-48.96%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-50.12%

Recent updates

Shareholder Returns

	A373110	KR Biotechs	KR Market
7D	-1.3%	-2.3%	-1.9%
1Y	n/a	14.9%	-9.5%

Return vs Industry: Insufficient data to determine how A373110 performed against the KR Biotechs industry.

Return vs Market: Insufficient data to determine how A373110 performed against the KR Market.

Price Volatility

Is A373110's price volatile compared to industry and market?
A373110 volatility
A373110 Average Weekly Movement	10.7%
Biotechs Industry Average Movement	8.8%
Market Average Movement	6.6%
10% most volatile stocks in KR Market	12.8%
10% least volatile stocks in KR Market	3.3%

Stable Share Price: A373110's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: Insufficient data to determine A373110's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	61	n/a	xcell.co.kr/kor/

Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. Xcell Therapeutics Inc. was incorporated in 2015 and is based in Seoul, South Korea.

Xcell Therapeutics Inc. Fundamentals Summary

How do Xcell Therapeutics's earnings and revenue compare to its market cap?
A373110 fundamental statistics
Market cap	₩43.73b
Earnings (TTM)	-₩9.79b
Revenue (TTM)	₩1.95b

23.3x

P/S Ratio

-4.6x

P/E Ratio

Is A373110 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A373110 income statement (TTM)
Revenue	₩1.95b
Cost of Revenue	₩3.27b
Gross Profit	-₩1.32b
Other Expenses	₩8.47b
Earnings	-₩9.79b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-896.73
Gross Margin	-67.99%
Net Profit Margin	-503.34%
Debt/Equity Ratio	41.7%

How did A373110 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 14:00
End of Day Share Price	2024/12/26 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xcell Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Xcell Therapeutics KOSDAQ:A373110 Stock Report